Skip to main content
OBI's acute lymphoblastic leukemia candidate gets FDA orphan status
9/20/2018

OBI Pharma's OBI-3424, which is being developed to treat patients with acute lymphoblastic leukemia, was granted orphan drug status by the FDA.

Full Story: